What’s happening at the annual EAU meeting in Munich?


So our friends at UroToday have started providing reports on the key presentations that are being given at the annual meeting of the European Association of Urology, being held this year in Munich, Germany. Here are links to some interesting reports (but do remember that you can only see these reports if you register with UroToday, which is free to users):

According to UroToday, Godtman presented data from the 18-year (and last) update of the Gõteborg prostate cancer screening trial in Sweden. Do remember that the patients enrolled in this screening trial were PSA use naive back in 1994, when the trial started. Yes the trial did show that you would find 1 case of prostate cancer for each of 10 men actually screened (and for each 231 men invited for screening). However, it also showed that on a population basis the chances of actually finding prostate cancer in the screened population dropped significantly over time. The hazard ratio (HR) for prostate cancer incidence among the screened population as opposed to the unscreened control patients dropped from HR = 4.5 at the first screening round to HR = 1.1 after 15+ years of testing. And of course there is then the question of what percentage of the cancers actually found were clinically significant.

When it comes to the potential of individualized or precision medicine in the treatment of progressive, metastatic prostate cancer, UroToday reports that Dr. Steven Bova of John Hopkins gave an update on his long-term studies into the genetics and genomics of metastatic, castration-resistant prostate cancer and the difference between “monoclonal” and “polyclonal” seeding of metastasis over time. The latter tends to be a great deal more aggressive. On the same general topic, they also report on a presentation by Schlomm on the ability of genomics to predict risk for aggressive, metastatic disease. They state that Dr. Schlomm is trying to “create a molecular speedometer for each patient in order to precisely predict individual patient prognosis.”

A fourth report is on a presentation by Fanti that deals with current perspectives on the use of PET/CT scan imaging in the management of prostate cancer.

And last but by no means least is a report on a presentation by Johannsson on quality of life and prostate cancer treatment. She apparently concluded that:

minimizing negative perceived side-effects should remain a high priority in prostate cancer care. We need to avoid over-treatment. We also need to provide appropriate counseling to all patients on evolving side effects with time and aging. Patients who choose [active surveillance or watchful waiting] should also be counseled about need for further therapy and increased rates of ED or incontinence with time as cancer progresses.

That’s a conclusion that a lot of more experienced patients and advocates will be pleased to hear.

One Response

  1. Thanks for sharing the UroToday links! You do such great work overall and we were delighted to get noticed by you this morning!

    Thank you

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: